Circulating tumour cells from patients with colorectal cancer have cancer stem cell hallmarks in ex vivo culture

Gut

Volumn 66, Issue 10, 2017, Pages 1802-1810

  Grillet, Fanny ^a,b,c   Bayet, Elsa ^a,b,c   Villeronce, Olivia ^a,b,c   Zappia, Luke ^d   Lagerqvist, Ebba Louise ^a,b,c   Lunke, Sebastian ^d   Charafe Jauffret, Emmanuelle ^e   Pham, Kym ^d   Molck, Christina ^d   Rolland, Nathalie ^f   Bourgaux, Jean François ^f   Prudhomme, Michel ^f   Philippe, Claire ^f   Bravo, Sophie ^f   Boyer, Jean Christophe ^f   Canterel Thouennon, Lucile ^g   Taylor, Graham Roy ^d   Hsu, Arthur ^d   Pascussi, Jean Marc ^a,b,c   Hollande, Frédéric ^a,b,c,d   Pannequin, Julie ^a,b,c   more..

^a INSTITUT DE GÉNOMIQUE FONCTIONNELLE   (France)

^b INSERM   (France)

^c UNIV MONTPELLIER   (France)

^d UNIVERSITY OF MELBOURNE   (Australia)

^e AIX MARSEILLE UNIVERSITY   (France)

^f DEPARTMENT OF NEUROLOGY   (France)

^g INSTITUT DE RECHERCHE EN CANCÉROLOGIE DE MONTPELLIER   (France)

Author keywords

Colorectal Cancer; Drug Toxicity; Liver Metastases

Indexed keywords

ALDEHYDE DEHYDROGENASE; CD133 ANTIGEN; CD44V6 ANTIGEN; CHROMOGRANIN A; DIPEPTIDYL PEPTIDASE IV; EPITHELIAL CELL ADHESION MOLECULE; FIRTECAN; FLUOROURACIL; MESSENGER RNA; MUCIN 2; REGORAFENIB; VEMURAFENIB; VILLIN; ALDH1A1 PROTEIN, HUMAN; ANTINEOPLASTIC AGENT; HERMES ANTIGEN; RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER RESISTANCE; CANCER STEM CELL; CARCINOGENICITY; CELL DIFFERENTIATION; CELL SELF-RENEWAL; CIRCULATING TUMOR CELL; COLORECTAL CARCINOMA; CONTROLLED STUDY; DRUG SENSITIVITY; GENE EXPRESSION; GENE IDENTIFICATION; GENETIC HETEROGENEITY; HUMAN; HUMAN CELL; LIVER METASTASIS; METASTASIS POTENTIAL; METASTATIC COLORECTAL CANCER; NONHUMAN; PERSONALIZED MEDICINE; PRIORITY JOURNAL; RNA SEQUENCE; TUMOR XENOGRAFT; ANIMAL; BLOOD; CANCER TRANSPLANTATION; COLORECTAL TUMOR; DRUG INACTIVATION; DRUG RESISTANCE; ENZYMOLOGY; GENETICS; LIVER TUMOR; METABOLISM; MOUSE; PATHOLOGY; PHENOTYPE; PHYSIOLOGY; PRIMARY CELL CULTURE; SECONDARY; SEQUENCE ANALYSIS; TUMOR CELL CULTURE; TUMOR EMBOLISM; UPREGULATION;

ALDEHYDE DEHYDROGENASE; ANIMALS; ANTIGENS, CD44; ANTINEOPLASTIC AGENTS; CELL DIFFERENTIATION; CELL SELF RENEWAL; COLORECTAL NEOPLASMS; DIPEPTIDYL PEPTIDASE 4; DRUG RESISTANCE, NEOPLASM; HUMANS; INACTIVATION, METABOLIC; LIVER NEOPLASMS; MICE; NEOPLASM TRANSPLANTATION; NEOPLASTIC CELLS, CIRCULATING; NEOPLASTIC STEM CELLS; PHENOTYPE; PRIMARY CELL CULTURE; RNA, NEOPLASM; SEQUENCE ANALYSIS, RNA; TUMOR CELLS, CULTURED; UP-REGULATION;

EID: 84979622730     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gutjnl-2016-311447     Document Type: Article

References (64)

1. Dobrila-Dintinjana R, Vanis N, Dintinjana M, et al. Etiology and oncogenesis of pancreatic carcinoma. Coll Antropol 2012;36:1063-7.
2. Chaffer CL, Weinberg RA. A perspective on cancer cell metastasis. Science 2011;331:1559-64.
3. Gupta GP, Massagué J. Cancer metastasis: Building a framework. Cell 2006;127:679-95.
4. Cohen SJ, Punt CJ, Iannotti N, et al. Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. J Clin Oncol 2008;26:3213-21.
5. Ramsköld D, Luo S, Wang YC, et al. Full-length mRNA-Seq from single-cell levels of RNA and individual circulating tumor cells. Nat Biotechnol 2012;30:777-82.
6. Lohr JG, Adalsteinsson VA, Cibulskis K, et al. Whole-exome sequencing of circulating tumor cells provides a window into metastatic prostate cancer. Nat Biotechnol 2014;32:479-84.
7. Powell AA, Talasaz AH, Zhang H, et al. Single cell profiling of circulating tumor cells: Transcriptional heterogeneity and diversity from breast cancer cell lines. PLoS ONE 2012;7:e33788.
8. Yu M, Bardia A, Wittner BS, et al. Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition. Science 2013;339:580-4.
9. Yokobori T, Iinuma H, Shimamura T, et al. Plastin3 is a novel marker for circulating tumor cells undergoing the epithelial-mesenchymal transition and is associated with colorectal cancer prognosis. Cancer Res 2013;73:2059-69.
10. Pecot CV, Bischoff FZ, Mayer JA, et al. A novel platform for detection of CK+ and CK-CTCs. Cancer Discov 2011;1:580-6.
11. Baccelli I, Schneeweiss A, Riethdorf S, et al. Identification of a population of blood circulating tumor cells from breast cancer patients that initiates metastasis in a xenograft assay. Nat Biotechnol 2013;31:539-44.
12. Hodgkinson CL, Morrow CJ, Li Y, et al. Tumorigenicity and genetic profiling of circulating tumor cells in small-cell lung cancer. Nat Med 2014;20:897-903.
13. Tinhofer I, Saki M, Niehr F, et al. Cancer stem cell characteristics of circulating tumor cells. Int J Radiat Biol 2014;90:622-7.
14. Yu M, Bardia A, Aceto N, et al. Cancer therapy. Ex vivo culture of circulating breast tumor cells for individualized testing of drug susceptibility. Science 2014;345:216-20.
15. Gao D, Vela I, Sboner A, et al. Organoid cultures derived from patients with advanced prostate cancer. Cell 2014;159:176-87.
16. Bobek V, Gurlich R, Eliasova P, et al. Circulating tumor cells in pancreatic cancer patients: Enrichment and cultivation. World J Gastroenterol 2014;20:17163-70.
17. Kolostova K, Matkowski R, Gürlich R, et al. Detection and cultivation of circulating tumor cells in gastric cancer. Cytotechnology Published Online First: 11 Apr 2015. doi:10.1007/s10616-015-9866-9
18. Bidard FC, Ferrand FR, Huguet F, et al. Disseminated and circulating tumor cells in gastrointestinal oncology. Crit Rev Oncol Hematol 2012;82:103-15.
19. Hu Y, Smyth GK. ELDA: Extreme limiting dilution analysis for comparing depleted and enriched populations in stem cell and other assays. J Immunol Methods 2009;347:70-8.
20. Touil Y, Igoudjil W, Corvaisier M, et al. Colon cancer cells escape 5FU chemotherapy-induced cell death by entering stemness and quiescence associated with the c-Yes/YAP axis. Clin Cancer Res 2014;20:837-46.
21. Huang EH, Hynes MJ, Zhang T, et al. Aldehyde dehydrogenase 1 is a marker for normal and malignant human colonic stem cells (SC) and tracks SC overpopulation during colon tumorigenesis. Cancer Res 2009;69:3382-9.
22. Pang R, Law WL, Chu AC, et al. A subpopulation of CD26+ cancer stem cells with metastatic capacity in human colorectal cancer. Cell Stem Cell 2010;6:603-15.
23. Todaro M, Gaggianesi M, Catalano V, et al. CD44v6 is a marker of constitutive and reprogrammed cancer stem cells driving colon cancer metastasis. Cell Stem Cell 2014;14:342-56.
24. Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol 2014;15:550.
25. Ritchie ME, Phipson B, Wu D, et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res 2015;43: E47.
26. Law CW, Chen Y, Shi W, et al. voom: Precision weights unlock linear model analysis tools for RNA-seq read counts. Genome Biol 2014;15:R29.
27. Onstenk W, Sieuwerts AM, Weekhout M, et al. Gene expression profiles of circulating tumor cells versus primary tumors in metastatic breast cancer. Cancer Lett 2015;362:36-44.
28. Mostert B, Sieuwerts AM, Kraan J, et al. Gene expression profiles in circulating tumor cells to predict prognosis in metastatic breast cancer patients. Ann Oncol 2015;26:510-16.
29. Luo X, Mitra D, Sullivan RJ, et al. Isolation and molecular characterization of circulating melanoma cells. Cell Rep 2014;7:645-53.
30. Smirnov DA, Zweitzig DR, Foulk BW, et al. Global gene expression profiling of circulating tumor cells. Cancer Res 2005;65:4993-7.
31. Luo W, Friedman MS, Shedden K, et al. GAGE: Generally applicable gene set enrichment for pathway analysis. BMC Bioinformatics 2009;10:161.
32. Corcoran RB, Ebi H, Turke AB, et al. EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib. Cancer Discov 2012;2:227-35.
33. Brabletz T, Jung A, Spaderna S, et al. Opinion: Migrating cancer stem cells-an integrated concept of malignant tumour progression. Nat Rev Cancer 2005;5:744-9.
34. Kasimir-Bauer S, Hoffmann O, Wallwiener D, et al. Expression of stem cell and epithelial-mesenchymal transition markers in primary breast cancer patients with circulating tumor cells. Breast Cancer Res 2012;14:R15.
35. Markiewicz A, Ksikiewicz M, Wenicka-Jakiewicz M, et al. Mesenchymal phenotype of CTC-enriched blood fraction and lymph node metastasis formation potential. PLoS ONE 2014;9:e93901.
36. Katoh S, Goi T, Naruse T, et al. Cancer stem cell marker in circulating tumor cells: Expression of CD44 variant exon 9 is strongly correlated to treatment refractoriness, recurrence and prognosis of human colorectal cancer. Anticancer Res 2015;35:239-44.
37. Iinuma H, Watanabe T, Mimori K, et al. Clinical significance of circulating tumor cells, including cancer stem-like cells, in peripheral blood for recurrence and prognosis in patients with Dukes' stage B and C colorectal cancer. J Clin Oncol 2011;29:1547-55.
38. Pakneshan S, Salajegheh A, Smith RA, et al. Clinicopathological relevance of BRAF mutations in human cancer. Pathology 2013;45:346-56.
39. Artale S, Sartore-Bianchi A, Veronese SM, et al. Mutations of KRAS and BRAF in primary and matched metastatic sites of colorectal cancer. J Clin Oncol 2008;26:4217-19.
40. Paliogiannis P, Cossu A, Tanda F, et al. Mutational concordance between primary and metastatic colorectal adenocarcinoma. Oncol Lett 2014;8:1422-6.
41. Gundem G, Van Loo P, Kremeyer B, et al. The evolutionary history of lethal metastatic prostate cancer. Nature 2015;520:353-7.
42. Hong MK, Macintyre G, Wedge DC, et al. Tracking the origins and drivers of subclonal metastatic expansion in prostate cancer. Nat Commun 2015;6:6605.
43. Onstenk W, Kraan J, Mostert B, et al. Improved Circulating Tumor Cell Detection by a Combined EpCAM and MCAM CellSearch Enrichment Approach in Patients with Breast Cancer Undergoing Neoadjuvant Chemotherapy. Mol Cancer Ther 2015;14:821-7.
44. Mostert B, Sieuwerts AM, Bolt-de Vries J, et al. mRNA expression profiles in circulating tumor cells of metastatic colorectal cancer patients. Mol Oncol 2015;9:920-32.
45. Ma SR, Wang WM, Huang CF, et al. Anterior gradient protein 2 expression in high grade head and neck squamous cell carcinoma correlated with cancer stem cell and epithelial mesenchymal transition. Oncotarget 2015;6:8807-21.
46. Morisaki T, Yashiro M, Kakehashi A, et al. Comparative proteomics analysis of gastric cancer stem cells. PLoS ONE 2014;9:e110736.
47. Dalerba P, Dylla SJ, Park IK, et al. Phenotypic characterization of human colorectal cancer stem cells. Proc Natl Acad Sci USA 2007;104:10158-63.
48. Dvorak P, Dvorakova D, Hampl A. Fibroblast growth factor signaling in embryonic and cancer stem cells. FEBS Lett 2006;580:2869-74.
49. Valladares-Ayerbes M, Blanco-Calvo M, Reboredo M, et al. Evaluation of the adenocarcinoma-associated gene AGR2 and the intestinal stem cell marker LGR5 as biomarkers in colorectal cancer. Int J Mol Sci 2012;13:4367-87.
50. Castillo V, Valenzuela R, Huidobro C, et al. Functional characteristics of cancer stem cells and their role in drug resistance of prostate cancer. Int J Oncol 2014;45:985-94.
51. Guan DX, Shi J, Zhang Y, et al. Sorafenib enriches epithelial cell adhesion molecule-positive tumor initiating cells and exacerbates a subtype of hepatocellular carcinoma through TSC2-AKT cascade. Hepatology 2015;62:1791-803.
52. Fillmore CM, Gupta PB, Rudnick JA, et al. Estrogen expands breast cancer stem-like cells through paracrine FGF/Tbx3 signaling. Proc Natl Acad Sci USA 2010;107:21737-42.
53. Yu H, Zhao J, Lin L, et al. Proteomic study explores AGR2 as pro-metastatic protein in HCC. Mol Biosyst 2012;8:2710-18.
54. Bramswig KH, Poettler M, Unseld M, et al. Soluble carcinoembryonic antigen activates endothelial cells and tumor angiogenesis. Cancer Res 2013;73:6584-96.
55. Ni J, Cozzi PJ, Duan W, et al. Role of the EpCAM (CD326) in prostate cancer metastasis and progression. Cancer Metastasis Rev 2012;31:779-91.
56. Rangel LB, Agarwal R, D'Souza T, et al. Tight junction proteins claudin-3 and claudin-4 are frequently overexpressed in ovarian cancer but not in ovarian cystadenomas. Clin Cancer Res 2003;9:2567-75.
57. Alavi M, Mah V, Maresh EL, et al. High expression of AGR2 in lung cancer is predictive of poor survival. BMC Cancer 2015;15:655.
58. Gebauer F, Wicklein D, Horst J, et al. Carcinoembryonic antigen-related cell adhesion molecules (CEACAM) 1, 5 and 6 as biomarkers in pancreatic cancer. PLoS ONE 2014;9:e113023.
59. Morris KL, Tugwood JD, Khoja L, et al. Circulating biomarkers in hepatocellular carcinoma. Cancer Chemother Pharmacol 2014;74:323-32.
60. Hiraga T, Ito S, Nakamura H. EpCAM expression in breast cancer cells is associated with enhanced bone metastasis formation. Int J Cancer 2016;138:1698-708.
61. Ach T, Schwarz-Furlan S, Ach S, et al. Genomic aberrations of MDM2, MDM4, FGFR1 and FGFR3 are associated with poor outcome in patients with salivary gland cancer. J Oral Pathol Med Published Online First: 14 Dec 2015. doi:10.1111/jop. 12394
62. Toss A, Mu Z, Fernandez S, et al. CTC enumeration and characterization: Moving toward personalized medicine. Ann Transl Med 2014;2:108.
63. Gong C, Liu B, Yao Y, et al. Potentiated DNA Damage Response in Circulating Breast Tumor Cells Confers Resistance to Chemotherapy. J Biol Chem 2015;290:14811-25.
64. Cayrefourcq L, Mazard T, Joosse S, et al. Establishment and characterization of a cell line from human circulating colon cancer cells. Cancer Res 2015;75:892-901.